Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells

International Journal of Oncology

Volumn 33, Issue 1, 2008, Pages 121-127

  Prados, Jose ^a,b   Melguizo, Consolacion ^a,b   Rama, Ana ^a,b   Ortiz, Raul ^a,b   Boulaiz, Houria ^a,b   Rodriguez Serrano, Fernando ^c   Caba, Octavio ^c   Rodriguez Herba, Jose Juan ^d   Ramos, Juan Luis ^d   Aranega, Antonia ^a,b  

^a Facultad de Medicina   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d CSIC   (Spain)

Author keywords

Combined therapy; Cytotoxic theraphy; Gef gene; Gene therapy; Lung cancer

Indexed keywords

ESCHERICHIA COLI PROTEIN; GEF PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; BACTERIAL TOXIN; HOKC PROTEIN, E COLI; MEMBRANE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL; SUICIDE GENE THERAPY; TUMOR SPHEROID; TUMOR VOLUME; APOPTOSIS; GENE THERAPY; GENETICS; LUNG TUMOR; MULTICELLULAR SPHEROID; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BACTERIAL TOXINS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ESCHERICHIA COLI PROTEINS; GENE THERAPY; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; PACLITAXEL; SPHEROIDS, CELLULAR;

EID: 51049106657     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.33.1.121     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer Statistics 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun, D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V and Chastang C: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIa non-small-cell lung cancer. J Clin Oncol 20: 247-253, 2002.
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15: 1782-1789, 2004.
4. Toloza EM and D'Amico TA: Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg 17: 199-204, 2005.
5. Toloza EM: Gene therapy for lung cancer. Thorac Surg Clin 16: 397-419, 2006.
6. Shieh GS, Shiau AL, Yo YT, Lin PR, Chang CC, Tzai TS and Wu CL: Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 66: 9957-9966, 2006.
7. Deharvengt S, Rejiba S, Wack S, Aprahamian M and Hajri A: Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol 30: 1397-1406, 2007.
8. Mavria G, Harrington KJ, Marshall CJ and Porter CD: In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy. J Gene Med 7: 263-275, 2005.
9. Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S, Chang M, Lanuti M, Black ME, Kaiser LR and Albelda SM: Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 10: 353-364, 2003.
10. Dachs GU, Tupper J and Tozer GM: From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16: 349-359, 2005.
11. Boulaiz H, Prados J, Melguizo C, García A, Marchal JA, Carrillo E, Ramos JL and Aránega A: Inhibition of cell proliferation and apoptosis induction in human melanoma MCF7 cell line by gef gene. Br J Cancer 89: 192-198, 2003.
12. Boulaiz H, Prados J, Marchal JA, García A, Alvarez L, Melguizo C, Carrillo E, Ramos JL and Aránega A: Transfection of MS-36 melanoma cells with gef gene inhibits proliferation and induces modulation of cell cycle. Cancer Science 94: 564-568, 2003.
13. Gerdes K, Poulsen LK, Thisted T, Nielsen AK, Martinussen J and Anderssen PH: The hok killer gene family in Gram negative bacteria. New Biol 2: 946-956, 1990.
14. Poulsen LK, Refn A, Molin S and Andersson P: Topographic analysis of the toxic gef protein from E. Coli. Mol Microbiol 5: 1639-1648, 1991.
15. Molin SL, Boe LB, Jensen CS, Kristensen M, Givskov M, Ramos JL and Bej AK: Suicidal genetic elements and their use in biological containment of bacteria. Annu Rev Microbiol 47: 139-166, 1993.
16. Odot J, Albert P, Cartier A, Tarpin M, Devy J and Madoulet C: In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111: 381-387, 2004.
17. Boyd M, Mairs SC, Stevenson K, Livingstone A, Clark AM, Ross SC and Mairs RJ: Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. J Gene Med 4: 567-576, 2002.
18. Monazzam A, Razifar P, Simonsson M, Qvarnström F, Josephsson R, Blomqvist C, Langström B and Bergström M: Multicellular tumour spheroid as a model for evaluation of 18FFDG as biomarker for breast cancer treatment monitoring. Cancer Cell Int 6: 6, 2006.
19. Fang B and Roth JA: The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther 5: 475-482, 2003.
20. Määttä AM, Tenhunen A, Pasanen T, Meriläinen O, Pellinen R, Mäkinen K, Alhava E and Wahlfors A: Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol 24: 943-949, 2004.
21. Pedersen N, Pedersen MW, Lan MS, Breslin MB and Poulsen HS: The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther 13: 375-384, 2006.
22. Van Dillen IJ, Mulder NE, Sluiter WJ, Meijer C, De Jong S, Loncarek J, Mesnil M, De Vries EF, Vaalburg W and Hospers GA: Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ ganciclovir-induced bystander effect in a human small cell lung cancer cell line model. Anticancer Res 25: 255-261, 2005.
23. McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB and Heller R: Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 14: 647-655, 2006.
24. Agu CA, Klein R, Lengler J, Schilcher F, Gregor W, Peterbauer T, Blasi U, Salmons B, Gunzburg WH and Hohenadl C: Bacterio-phage-encoded toxins: the lambdaholin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells. Cell Microbiol 9: 1753-1765, 2007.
25. Zarovni N, Vago R, Soldá T, Monoco L and Fabbrini MS: Saporin as a novel suicide gene in anticancer gene therapy. Cancer Gene Ther 14: 165-173, 2007.
26. Narumi K, Kojima A and Crystal RG: Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo. Am J Respir Cell Biol 19: 936-941, 1998.
27. Katabi M, Yuan S, Chan H, Galipeau J and Batist G: The non-apoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region. Mol Ther 5: 170-176, 2002.
28. Ronchel M and Ramos JL: Dual system to reinforce biological containment of recombinant bacteria designed for rhizomediation. Appl Environ Microbiol 67: 2649-2656, 2001.
29. Emelyanov VV: Mitochondrial connection to the origin of the eukaryotic cell. Eur J Biochem 270: 1599-1618, 2003.
30. Coelho A, Andrade JR, Vicente AC and Dirita VJ: Cytotoxic cell vacuolating activity from Vibrio cholerae hemolysin. Infect Immun 68: 1700-1705, 2000.
31. Szabó I, Brutsche S, Tombola F, Moschioni M, Satin B, Telford JL, Rappuoli R, Montecucco C, Papini E and Zoratti M: Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of Helicobacter pylori is required for its biological activity. EMBO J 18: 5517-5527, 1999.
32. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arum B, Booser DJ, Menander K, Van Wart Hood J, Vatero V and Hortobagyi GN: A non-replicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy and biologic activity of a novel gene-therapy approach. Cancer 107: 935-944, 2006.
33. Hao H, Dong YB, Bowling MT, Zhou HS and McMasters KM: Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin. Anticancer Res 26: 1947-1956, 2006.
34. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA and Ji L: Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer 7: 2887-2897, 2001.
35. Janát-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M and Kim SW: Combination of local, non-viral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 9: 829-836, 2004.
36. Janát-Amsbury MM, Yockman JW, Anderson ML, Kieback DG and Kim SW: Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res 26: 3223-3228, 2006.
37. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A and Sgouros G: Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 112: 713-721, 2004.
38. Schepelmann S and Springer CJ: Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 6: 647-670, 2006.
39. Poulsen TT, Pedersen N and Poulsen HS: Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer 6: 227-236, 2005.